8-KLeadership ChangesExhibits & Filings

PEPSICO INC 8-K Report, Executive Changes (Mar 14, 2014)

Filed March 14, 2014For Securities:PEP

Summary

PepsiCo, Inc. (PEP) filed an 8-K on March 14, 2014, reporting a change in its Board of Directors and amendments to its Long-Term Incentive Plan. Dr. Victor J. Dzau resigned from the Board, effective immediately, due to his upcoming appointment as President of the Institute of Medicine on July 1, 2014. This change in directorship is noted, though the direct impact on day-to-day operations or financial performance is not detailed in this filing. The more significant development for investors likely lies in the amendments approved for the Amended and Restated PepsiCo, Inc. 2007 Long-Term Incentive Plan. These changes aim to enhance transparency and align with longstanding practices, specifically by clarifying provisions that prohibit the repricing of stock options and stock appreciation rights without shareholder approval. Crucially, the amendments now explicitly forbid the cancellation of underwater options or SARs for cash or other securities. Additionally, minimum vesting periods for equity awards have been extended to include stock options and stock appreciation rights, reinforcing a commitment to long-term employee alignment and potentially impacting future equity-based compensation structures.

Key Highlights

  • 1Resignation of Dr. Victor J. Dzau from the Board of Directors, effective March 13, 2014.
  • 2Dr. Dzau's resignation is due to his appointment as President of the Institute of Medicine.
  • 3Amendments approved for the Amended and Restated PepsiCo, Inc. 2007 Long-Term Incentive Plan.
  • 4Clarification of provisions prohibiting repricing of stock options and stock appreciation rights without shareholder approval.
  • 5Explicit prohibition against cancelling underwater options or stock appreciation rights for cash or other securities.
  • 6Extension of minimum vesting provisions for time-based equity awards to include stock options and stock appreciation rights.

Frequently Asked Questions

Dr. Dzau resigned from the Board of Directors due to his upcoming appointment as President of the Institute of Medicine, effective July 1, 2014. He offered his resignation in accordance with the company's Corporate Governance Guidelines.

The Long-Term Incentive Plan was amended to clarify existing provisions. Specifically, it now explicitly prohibits the cancellation of underwater stock options or stock appreciation rights (SARs) in exchange for cash or other securities, in addition to prohibiting repricing without shareholder approval. The minimum vesting periods for time-based equity awards were also extended to apply to stock options and SARs.

These amendments reinforce PepsiCo's commitment to long-term alignment between management and shareholders by preventing actions that could be perceived as dilutive or unfair, such as repricing underwater options or compensating executives for options that have lost value without shareholder consent. The extended vesting periods also encourage a longer-term perspective for equity award recipients.

This 8-K filing does not indicate any immediate financial implications for PepsiCo stemming from Dr. Dzau's resignation. His departure is attributed to a new professional commitment.